IPH Innate Pharma

By Colin Kellaher

Shares of Innate Pharma dropped in premarket trading Thursday after the biopharmaceutical company said the U.S. Food and Drug Administration placed a partial hold on studies of its lead proprietary program lacutamab following the death of a patient.

Innate said the partial hold, which pauses new patient enrollment in its ongoing Phase 2 and Phase 1b studies of lacutamab, follows a fatal case of hemophagocytic lymphohistiocytosis, a rare hematologic disorder.

The Marseille, France, company said it is working to address requests from the FDA, including the incorporation of risk mitigation and management strategies for hemophagocytic lymphohistiocytosis in the lacutamab studies.

Innate noted that patients already on study treatment who are deriving clinical benefit can continue treatment, and that it doesn't expect any delay in the Phase 2 study data, as all patients had already been recruited.

Innate shares, which closed Wednesday at $2.47, were recently down 11% to $2.19 in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 05, 2023 07:59 ET (11:59 GMT)

Innate Pharma (EU:IPH)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Innate Pharma (EU:IPH)
Historical Stock Chart
Von Mai 2023 bis Mai 2024